Altered Binding Site Selection of p53 Transcription Cassettes by Hepatitis B Virus X Protein

REFERENCES

• Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307–310.
   PubMed Web of Science ®Google Scholar
• Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091.
   PubMed Web of Science ®Google Scholar
• Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711.
   PubMed Web of Science ®Google Scholar
• Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764–2772.
   PubMedGoogle Scholar
• Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325–334.
   PubMed Web of Science ®Google Scholar
• Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1805–1814.
   PubMed Web of Science ®Google Scholar
• Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. 2004. Regulation of p53 activity through lysine methylation. Nature 432:353–360.
   PubMed Web of Science ®Google Scholar
• Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606.
   PubMed Web of Science ®Google Scholar
• Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:2259–2264.
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849–862.
   PubMed Web of Science ®Google Scholar
• Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, Ketner G, Branton PE. 1997. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:3788–3798.
   PubMed Web of Science ®Google Scholar
• Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J. Virol. 83:4652–4669.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136.
   PubMed Web of Science ®Google Scholar
• Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. 1998. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16:349–357.
   PubMed Web of Science ®Google Scholar
• Lechner MS, Laimins LA. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:4262–4273.
   PubMed Web of Science ®Google Scholar
• Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045–3052.
   PubMed Web of Science ®Google Scholar
• Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388:236–247.
   PubMed Web of Science ®Google Scholar
• Zhao LY, Santiago A, Liu J, Liao D. 2007. Repression of p53-mediated transcription by adenovirus E1B 55-kDa does not require corepressor mSin3A and histone deacetylases. J. Biol. Chem. 282:7001–7010.
   PubMedGoogle Scholar
• Kim CM, Koike K, Saito I, Miyamura T, Jay G. 1991. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317–320.
   PubMed Web of Science ®Google Scholar
• Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. 1994. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19:810–819.
   PubMed Web of Science ®Google Scholar
• Madden CR, Finegold MJ, Slagle BL. 2001. Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J. Virol. 75:3851–3858.
   PubMedGoogle Scholar
• Seifer M, Hohne M, Schaefer S, Gerlich WH. 1991. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J. Hepatol 13(Suppl. 4):S61–S65.
   PubMedGoogle Scholar
• Doria M, Klein N, Lucito R, Schneider RJ. 1995. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 14:4747–4757.
   PubMed Web of Science ®Google Scholar
• Henkler F, Hoare J, Waseem N, Goldin RD, McGarvey MJ, Koshy R, King IA. 2001. Intracellular localization of the hepatitis B virus HBx protein. J. Gen. Virol. 82:871–882.
   PubMed Web of Science ®Google Scholar
• Hoare J, Henkler F, Dowling JJ, Errington W, Goldin RD, Fish D, McGarvey MJ. 2001. Subcellular localisation of the X protein in HBV infected hepatocytes. J. Med. Virol. 64:419–426.
   PubMedGoogle Scholar
• Rahmani Z, Huh KW, Lasher R, Siddiqui A. 2000. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J. Virol. 74:2840–2846.
   PubMed Web of Science ®Google Scholar
• Takada S, Shirakata Y, Kaneniwa N, Koike K. 1999. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 18:6965–6973.
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Zhu M, Duan LX, London WT. 1993. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109–1117.
   PubMed Web of Science ®Google Scholar
• Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. 1995. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69:1851–1859.
   PubMed Web of Science ®Google Scholar
• Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U. S. A. 91:2230–2234.
   PubMed Web of Science ®Google Scholar
• Maguire HF, Hoeffler JP, Siddiqui A. 1991. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 252:842–844.
   PubMed Web of Science ®Google Scholar
• Williams JS, Andrisani OM. 1995. The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB. Proc. Natl. Acad. Sci. U. S. A. 92:3819–3823.
   PubMed Web of Science ®Google Scholar
• Choi BH, Choi M, Jeon HY, Rho HM. 2001. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol. 20:75–80.
   PubMedGoogle Scholar
• Sung WK, Lu Y, Lee CW, Zhang D, Ronaghi M, Lee CG. 2009. Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. J. Biol. Chem. 284:21941–21954.
   PubMed Web of Science ®Google Scholar
• Cougot D, Wu Y, Cairo S, Caramel J, Renard CA, Levy L, Buendia MA, Neuveut C. 2007. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem. 282:4277–4287.
   PubMed Web of Science ®Google Scholar
• Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. 1997. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 57:5137–5142.
   PubMedGoogle Scholar
• Ogden SK, Lee KC, Barton MC. 2000. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. J. Biol. Chem. 275:27806–27814.
   PubMed Web of Science ®Google Scholar
• Chung TW, Lee YC, Ko JH, Kim CH. 2003. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 63:3453–3458.
   PubMed Web of Science ®Google Scholar
• Lee AT, Ren J, Wong ET, Ban KH, Lee LA, Lee CG. 2005. The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J. Biol. Chem. 280:33525–33535.
   PubMedGoogle Scholar
• Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. U. S. A. 99:8467–8472.
   PubMed Web of Science ®Google Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207–219.
   PubMed Web of Science ®Google Scholar
• Ryoo HD, Gorenc T, Steller H. 2004. Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. Dev. Cell 7:491–501.
   PubMed Web of Science ®Google Scholar
• Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G. 2003. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J. Biol. Chem. 278:12310–12318.
   PubMed Web of Science ®Google Scholar
• Liu Y, Colosimo AL, Yang XJ, Liao D. 2000. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell. Biol. 20:5540–5553.
   PubMedGoogle Scholar
• Olsson A, Manzl C, Strasser A, Villunger A. 2007. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 14:1561–1575.
   PubMed Web of Science ®Google Scholar
• Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. 2006. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173:533–544.
   PubMed Web of Science ®Google Scholar
• Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, Wang JY, Anderson CW, Appella E, Xu Y. 2006. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26:6859–6869.
   PubMed Web of Science ®Google Scholar
• Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y. 2003. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 63:8948–8954.
   PubMed Web of Science ®Google Scholar